MDD XR 50 Tablet contains Desvenlafaxine 50 mg, a serotonin-norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of major depressive disorder (MDD). Desvenlafaxine exerts its therapeutic effect by inhibiting the reuptake of serotonin and norepinephrine, thereby enhancing neurotransmitter activity in the central nervous system, which helps alleviate depressive symptoms. MDD XR 50 Tablet is formulated for extended release, allowing for once-daily dosing and maintaining stable plasma drug concentrations over 24 hours. This medication is prescribed to improve mood, energy levels, and overall functioning in patients diagnosed with depression. Common adverse effects may include nausea, dizziness, insomnia, dry mouth, and increased sweating, though these are generally mild to moderate and tend to diminish with continued use. Caution is advised in patients with a history of bipolar disorder, seizures, or hypertension, and it should be used under close medical supervision in these populations. Abrupt discontinuation should be avoided due to potential withdrawal symptoms; therefore, gradual tapering is recommended. MDD XR 50 Tablet should not be combined with monoamine oxidase inhibitors (MAOIs) or other serotonergic agents to prevent the risk of serotonin syndrome. Regular monitoring and adherence to prescribed dosing are essential for optimal therapeutic outcomes.